Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 1
2008 1
2009 1
2010 2
2011 1
2012 2
2013 1
2014 2
2015 1
2016 2
2017 3
2018 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy.
Feng Q, Wei WQ, Chung CP, Levinson RT, Bastarache L, Denny JC, Stein CM. Feng Q, et al. Pharmacogenomics J. 2017 Mar;17(2):204-208. doi: 10.1038/tpj.2016.3. Epub 2016 Feb 23. Pharmacogenomics J. 2017. PMID: 26902539 Free PMC article.
Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and prevent cardiovascular disease. ...The therapeutic effect of statins may be modified by genetic variation in PCSK9
Statins (HMG-CoA reductase inhibitors) lower low-density lipoprotein cholesterol (LDL-C) and preve
The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients.
Wanmasae S, Sirintronsopon W, Porntadavity S, Jeenduang N. Wanmasae S, et al. Cardiovasc Ther. 2017 Dec;35(6). doi: 10.1111/1755-5922.12302. Epub 2017 Sep 25. Cardiovasc Ther. 2017. PMID: 28851085 Free article.
AIM: To investigate the effect of apolipoprotein E (APOE), cholesteryl ester transfer protein (CETP) and proprotein convertase subtilisin kexin type 9 (PCSK9) polymorphisms on the lipid-lowering response to simvastatin therapy in Thai hypercholesterole …
AIM: To investigate the effect of apolipoprotein E (APOE), cholesteryl ester transfer protein (CETP) and proprotein convertase subtil …
Resistance and intolerance to statins.
Reiner Z. Reiner Z. Nutr Metab Cardiovasc Dis. 2014 Oct;24(10):1057-66. doi: 10.1016/j.numecd.2014.05.009. Epub 2014 Jun 6. Nutr Metab Cardiovasc Dis. 2014. PMID: 24996502 Review.
BACKGROUND AND AIMS: Many patients treated with statins are considered statin-resistant because they fail to achieve adequate reduction of low density lipoprotein cholesterol (LDL-C) levels. ...However, currently, there is still not enough evidence to …
BACKGROUND AND AIMS: Many patients treated with statins are considered statin-resistant because they fail to achieve adequate …
Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
Pisciotta L, Sallo R, Rabacchi C, Wunsch A, Calandra S, Bertolini S. Pisciotta L, et al. Nutr Metab Cardiovasc Dis. 2012 Oct;22(10):831-5. doi: 10.1016/j.numecd.2011.04.003. Epub 2011 Sep 14. Nutr Metab Cardiovasc Dis. 2012. PMID: 21920719
We investigated the effect of L10 variant on basal lipid profile and response to statins in molecularly characterised FH patients. ...CONCLUSION: The variant L10 of the leucine repeats in PCSK9 signal peptide is to be considered as a factor capable of …
We investigated the effect of L10 variant on basal lipid profile and response to statins in molecularly characterised F …
The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis.
Davignon J, Dubuc G, Seidah NG. Davignon J, et al. Curr Atheroscler Rep. 2010 Sep;12(5):308-15. doi: 10.1007/s11883-010-0123-6. Curr Atheroscler Rep. 2010. PMID: 20623344 Review.
Recent advances have revealed a large number of genetic variants of PCSK9 that may modulate plasma cholesterol levels either positively or negatively, therefore influencing the risk of atherosclerosis. Recognition of these mutants may have clinical implicatio …
Recent advances have revealed a large number of genetic variants of PCSK9 that may modulate plasma cholesterol levels e …
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy.
Berge KE, Ose L, Leren TP. Berge KE, et al. Arterioscler Thromb Vasc Biol. 2006 May;26(5):1094-100. doi: 10.1161/01.ATV.0000204337.81286.1c. Epub 2006 Jan 19. Arterioscler Thromb Vasc Biol. 2006. PMID: 16424354
Also, the cholesterol-lowering effect of statins could be increased in subjects carrying mutations in the PCSK9 gene. ...CONCLUSIONS: The 4 missense mutations R46L, G106R, N157K, and R237W are associated with hypocholesterolemia and possibly increased …
Also, the cholesterol-lowering effect of statins could be increased in subjects carrying mutations in the PCSK9
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D, Pöss J, Böhm M, Laufs U. Urban D, et al. J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973703 Free article. Review.
Low intracellular cholesterol levels in response to statin treatment activate the sterol regulatory element-binding protein-2 (SREBP-2), resulting in coexpression of LDLR and PCSK9. Although this self-regulatory mechanism contributes to maintain cho
Low intracellular cholesterol levels in response to statin treatment activate the sterol regulatory element-binding pro …
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K, Sharma M, Ferdinand KC. Yadav K, et al. Nutr Metab Cardiovasc Dis. 2016 Oct;26(10):853-62. doi: 10.1016/j.numecd.2016.05.006. Epub 2016 May 30. Nutr Metab Cardiovasc Dis. 2016. PMID: 27352986 Review.
There is also significant variation of individual lipid-lowering. Following rapid development, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have progressed from genetic observations, to mechanistic studies, to closer realization of …
There is also significant variation of individual lipid-lowering. Following rapid development, proprotein convertase subtilisin/kexin …
Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population.
Polisecki E, Peter I, Robertson M, McMahon AD, Ford I, Packard C, Shepherd J, Jukema JW, Blauw GJ, Westendorp RG, de Craen AJ, Trompet S, Buckley BM, Murphy MB, Ordovas JM, Schaefer EJ; PROSPER Study Group. Polisecki E, et al. Atherosclerosis. 2008 Sep;200(1):95-101. doi: 10.1016/j.atherosclerosis.2007.12.005. Epub 2008 Feb 8. Atherosclerosis. 2008. PMID: 18262190 Free PMC article. Clinical Trial.
Caucasian carriers of the T allele at R46L in the proprotein convertase subtilisin/kexin type 9 (PCSK9) locus have been reported to have 15% lower low-density lipoprotein (LDL) cholesterol (C) levels and 47% lower coronary heart disease (CHD) risk. ...In this …
Caucasian carriers of the T allele at R46L in the proprotein convertase subtilisin/kexin type 9 (PCSK9) locus have been reported to h …
Effect of ezetimibe coadministered with statins in genotype-confirmed heterozygous FH patients.
Pisciotta L, Fasano T, Bellocchio A, Bocchi L, Sallo R, Fresa R, Colangeli I, Cantafora A, Calandra S, Bertolini S. Pisciotta L, et al. Atherosclerosis. 2007 Oct;194(2):e116-22. doi: 10.1016/j.atherosclerosis.2006.10.036. Epub 2006 Nov 30. Atherosclerosis. 2007. PMID: 17140581 Clinical Trial.
PCSK9 and NPC1L1 genes were analysed to assess the role of genetic variants in response to therapy. ...The variable response to statins was not due to PCSK9 gene variants associated with statin hyper-sensitivity. ...
PCSK9 and NPC1L1 genes were analysed to assess the role of genetic variants in response to therapy. ...The varia
15 results